engleski

BRAF mutant metastatic melanoma: A case report

Skin melanoma accounts for 4% of all dermatological malignancies, but it is responsible for about 80% mortality of skin tumors. Approximately 50 % of melanomas harbour activating point mutations in the BRAF gene. Specific BRAF inhibitors, in combination with MEK inhibitors are the mainstays of treatment in patients with advanced locoregional inoperable and metastatic BRAF-mutant melanoma. A 69-year-old woman was presented with a stage IIIC cutaneous nodular melanoma on the lower left leg.Histological examination showed a 11 x 10 mm large lesion with tumor thickness of 4 mm, without ulcer-ation (T4a), with large satellite nodules at 1mm distance from primary tumor and with present tumor infiltrating lymphocytes.

metastatic BRAFm melanoma, treatment

nije evidentirano